Amplify Treatments, Testing and Adv ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze. The portfolio maintains a sizable cost advantage over competitors, priced within the second-lowest fee quintile among peers.  

 The strategy's sensible investment philosophy merits an Above Average Process Pillar rating. Independent of the rating, analysis of the strategy's portfolio shows it has maintained a significant overweight position in liquidity exposure and volatility exposure compared with category peers. High liquidity exposure is attributed to stocks with a high trading volume, lending managers more flexibility. And high volatility exposure is rooted in stocks that have a higher standard deviation of returns. The team managing the passive strategy earns the strategy an Average People Pillar rating. The strategy's parent organization earns the firm a Below Average Parent Pillar rating, and this rating is inherited from vehicles belonging to the same branding entity and is indirectly assigned by an analyst.

Analyst Rating

Moderna

Quest Diagnostics

Alnylam Pharmaceuticals

Laboratory

ImmunityBio

Dynavax Technologies

QuidelOrtho Corp

Bio-Rad Laboratories

Vaxcyte

Vir Biotechnology

Morningstar's evaluation of this security's process aims to determine the likelihood that it will outperform its Morningstar Category index on a risk-adjusted basis over the long term. Amplify Treatments, Testing and Adv ETF earns an Above Average Process Pillar rating. The most meaningful contributor to the rating is that this fund tracks an index. Historical data, such as Morningstar's Active/Passive Barometer, finds that passively managed funds have generally outperformed their active counterparts, especially over longer time horizons. The firm's five-year retention rate of 93% also strengthens the process. Lastly, the process is limited by the parent firm's five-year risk-adjusted success ratio of 42%. The measure indicates the percentage of a firm's funds that survived and beat their respective category's median Morningstar Risk-Adjusted Return for the period. The parent's relatively low success ratio suggests that the firm could do better across its fund lineup.

The investment strategy as stated in the fund's prospectus is:  The investment seeks investment results that generally correlate to the total return performance of the Prime Treatments, Testing and Advancements Index.  Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and and provision of biological tests for patients. The fund is non-diversified. 

 The portfolio has allocations in its top two sectors, healthcare and financial services, that are similar to the category. The sectors with low exposure compared to category peers are basic materials and technology; however, the allocations are similar to the category. The portfolio is composed of 63 holdings and is quite concentrated. In particular, 50.6% of the strategy's assets are housed within the top 10 holdings, versus the category’s 38.7% average.

Above Average

Process

Amplify’s team earns An Average People Pillar rating. The main contributor to the rating is the firm's five-year retention rate of 93%. The size of the portfolio management team also contributes to the rating. With two portfolio managers, the fund is reasonably well-resourced. Lastly, the rating is limited by the managers' failure to consistently outperform peers at the funds they run, as measured by their combined three-year manager excess returns.

Average

People

While differentiated from much of the competition, Amplify ETFs' concentrated lineup of largely thematic exchange-traded funds harbors considerable risk. It earns a Below Average Parent Rating.

Amplify targets niches not previously explored by larger ETF firms. This leads to product launches in relatively narrow parts of the market like cannabis, online retail, and battery technology. A recent acquisition of 12 mostly thematic ETFs from ETF Managers Group only enhances this focus. Products like these tend to be extremely concentrated and volatile, inviting significant risks to their investors, not the least of which are ill-timed purchases and sales. Because of these risks, product success is unpredictable and leads to more closures than there are among traditional strategies. Since its 2016 founding, Amplify has merged or liquidated several ETFs that failed to gain traction or produced poor results.

Five subadvisors are responsible for the day-to-day management of Amplify's 29 ETFs. The firm regularly reviews subadvisor activity and performance and risk data but does not have a dedicated risk management team. Overall, its subadvisory relationships seem to emphasize product development and distribution rather than long-term, proven investment merit.

Amplify ETFs does what it sets out to do—offer investors differentiated ETF strategies—and leadership comes with considerable ETF experience. The firm's ETFs are not cheap but neither are they particularly pricey. Many levy category-competitive fees. Few of Amplify's ETFs should be considered core holdings, but they can serve a purpose for investors seeking specific exposures so long as shareholders understand the risks embedded.

Below Average

Parent

Amplify Treatments Testing & Advancements ETF

GERM tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases.

GERM tracks a tier-weighted index of US-listed healthcare companies engaged in treatments, testing, and other medical advancements. Holdings are selected by the index committee.

Amplify AI Powered Equity ETF

Amplify Travel Tech ETF

Amplify Etho Climate Leadership US ETF

Amplify Video Game Tech ETF

Amplify Cybersecurity ETF

Amplify Mobile Payments ETF

Amplify BlueStar Israel Technology ETF

Amplify Global Cloud Technology ETF

Amplify Alternative Harvest ETF

Amplify US Alternative Harvest ETF

Amplify Junior Silver Miners ETF

CHICAGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announced today it has completed its previously announced acquisition of ETF Managers Group (ETFMG) exchange-traded fund (ETF) assets, which consist of over $3.7 billion of assets under management (AUM) across 14 ETFs (as of 1/26/2024). Amplify ETFs will now manage $9.1 billion of AUM as of 1/26/2024.

Amplify ETFs Completes Acquisition to Reach $9.1 Billion AUM Across 31 ETFs

Breakwave Dry Bulk Shipping ETF

Amplify Transformational Data Sharing ETF

Breakwave Tanker Shipping ETF

Amplify Seymour Cannabis ETF

Amplify CWP Dividend & Option Income ETF

Amplify Online Retail ETF

In June, the ETF industry learned that issuer ETF Managers Group would be selling its funds to Amplify ETFs. The transaction, once completed, will bring Amplify's total AUM to $8 billion invested across 29 ETFs.

Amplify's Christian Magoon on Purchase of ETFMG's ETFs

Asian Growth CUBS ETF

TrueShares ESG Active Opportunities ETF

Hartford Schroders ESG US Equity ETF

Global X MSCI Nigeria ETF

Nightshares Russell 2000 ETF

Nightshares Russell 1000 ETF

Revere Sector Opportunity ETF

The week ending Friday, July 21, has been busy for the ETF industry, though launches were muted. A total of seven funds rolled out, which suggests the market could be entering some kind of summer slump.

This Week in ETFs: A Summer Slowdown

VanEck Vectors Biotech ETF

First Trust Morningstar Dividend Leaders Index Fund

Nasdaq Pharm Shs Nasdaq Pharmaceuticals

iShares Core High Dividend ETF

Invesco Nasdaq Biotechnology ETF

Horizon Kinetics Medical ETF

Novavax

Pfizer

Invesco Dynamic Pharmaceuticals ETF

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

Global X Longevity Thematic ETF 

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Clinical Trials ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

iShares Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares Global Healthcare ETF

iShares U.S. Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Merck

Novo Nordisk

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

ALPS Medical Breakthroughs ETF

Vanguard Health Care ETF

Wisdomtree BioRevolution Fund

SPDR S&P Biotech ETF

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

Global X Education ETF

Pacer BioThreat ETF

Direxion Work From Home ETF

COVID-themed stocks and ETFs were winners in 2020 and some parts of 2021 due to a spike in global coronavirus cases. We may see the same trend again as new COVID variants are 'pretty troublesome.

Here's Why COVID-Themed ETFs May Come Back Under the Radar

Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Genomics Immunology and Healthcare ETF (IDNA) fell 4.1%, ETFMG Treatments Testing and Advancements ETF (GERM) dropped 4.3%, SPDR S&P Biotech ETF (XBI) decreased 3.

Biotech ETFs Slip After Novavax Cuts 2022 Guidance

Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its latest quarterly report, along with a share buyback plan. On Wednesday, the Invesco Nasdaq Biotechnology ETF (IBBQ) increased 4.2%, the ETFMG Treatments Testing and Advancements ETF (GERM) advanced 5.

Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

Global X MSCI China Health Care ETF

Global X China Consumer ETF

iShares MSCI China ETF

Direxion mRNA ETF

SPDR FactSet Innovative Technology ETF

The first tranche of Chinese ADRs affected by a 2020 law has been released.

China ETFs Drop On Audit Enforcement

Johnson & Johnson

Biotech ETFs was the biggest gainer last week.

Biotech ETFs That Outperformed Last Week

Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.

Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs

VanEck Video Gaming and eSports ETF

iShares U.S. Home Construction ETF

iShares PHLX Semiconductor ETF

Simplify Volt RoboCar Disruption and Tech ETF

Though the broad markets ended the month in red, a few sector ETFs performed remarkably well.

5 Best Sector ETFs of November

The remainder of 2021 is expected to continue reeling under the spurt in coronavirus cases. Thus, a COVID-themed ETF could be a wise choice.

Bet On COVID-Themed ETFs as New Cases Rise Globally

ETF Managers Trust - ETFMG Treatments Testing and Advancements ETF is a biotech focused ETF invested in treatments and therapies firms.

GERM ETF: A New Player In The Infectious Disease Segment

First Trust Natural Gas ETF

Invesco Dynamic Energy Exploration & Production ETF

VanEck Rare Earth/Strategic Metals ETF

Sprott Uranium Miners ETF

SPDR S&P Retail ETF

Invesco S&P SmallCap Value with Momentum ETF

We highlight seven ETFs from different segments that have outperformed and gained more than 40% in the first nine months of 2021.

7 Best ETFs of the First Nine Months of 2021

Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases

The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.

Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan

Global X MSCI Argentina ETF

Roundhill Sports Betting & iGaming ETF

Global X Blockchain ETF

SPDR S&P Semiconductor ETF

Optimism about corporate earnings, U.S. FDA's full approval of Pfizer-BioNTech Covid-19 vaccine, some upbeat economic data points and the passage of the infrastructure bill helped key U.S. equity indexes go higher in August.

6 Best ETF Areas of August

Global X Cybersecurity ETF

First Trust Nasdaq Retail ETF

iShares U.S. Broker-Dealers & Securities Exchanges ETF

Invesco S&P 500 Equal Weight Materials ETF

Below are five ETFs that have gained from strong earnings results.

5 Must-Watch ETF Charts of Q2 Earnings

ETFs that look at a subsector of biotech have significantly outperformed broader biotech funds this year.

COVID Biotech ETFs Rise At Fever Pace

Wall Street analysts are bullish on stocks in almost two decades with about 56% of all recommendations on S&P 500 firms listed as buys, the highest since 2002.

ETFs to Buy on Most-Bullish Wall Street Outlook in Two Decades

The rest of 2021 is expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.

Are COVID-Themed ETFs Back in Focus as Delta Variant Fears Rise?

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Biohaven Pharmaceutical Hld

Biogen

Denali Therapeutics

Tekla Life Sciences Investors

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

InfraCap MLP

Global X Copper Miners ETF

VanEck Vectors Steel ETF

Simplify Volt Cloud and Cybersecurity Disruption ETF

April proved to be the solid month for the U.S. stock market with all the three major indices hovering near record highs.

5 Sector ETFs That Crushed the Market in April

News for Amplify Treatments Testing & Advancements ETF ETF (GERM)